Jan. 17 - Eli Lilly Canada Inc. is pleased to announce the Health Canada approval of BYETTATM (exenatide injection) for the treatment of adults with type 2 diabetes. BYETTA is indicated for use as a combination therapy with metformin and / or a sulfonylurea to improve blood sugar control in adults with type 2 diabetes who have not achieved adequate glycemic control on maximally tolerated doses of these oral therapies in addition to diet and exercise.
Byetta is peptide with 39 aminoacids and is very effective in controlling the blood glucose levels and is approved in US also.
No comments:
Post a Comment